June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Effect of reticular pseudodrusen on progression to late age-related macular degeneration alongside traditional severity scales
Author Affiliations & Notes
  • Elvira Agron
    National Eye Institute, Bethesda, Maryland, United States
  • Tiarnan D L Keenan
    National Eye Institute, Bethesda, Maryland, United States
  • Traci E Clemons
    The Emmes Company LLC, Rockville, Maryland, United States
  • Emily Y Chew
    National Eye Institute, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Elvira Agron None; Tiarnan Keenan None; Traci Clemons None; Emily Chew None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 336 – F0167. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elvira Agron, Tiarnan D L Keenan, Traci E Clemons, Emily Y Chew; Effect of reticular pseudodrusen on progression to late age-related macular degeneration alongside traditional severity scales. Invest. Ophthalmol. Vis. Sci. 2022;63(7):336 – F0167.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate reticular pseudodrusen (RPD) as a risk factor for progression to late age-related macular degeneration (AMD)

Methods : Color fundus photographs (CFP) of participants enrolled in the Age-Related Eye Diseases Study (AREDS) from annual study visits were graded for large drusen, pigmentary abnormalities, and late AMD. RPD presence was determined by deep learning grading of CFP. Proportional hazards regressions were performed that included traditional AMD severity scales (simplified severity scale (person) and 9-step scale (eye)) based upon the presence of drusen and pigmentary changes and RPD presence together. Outcomes were late AMD, geographic atrophy (GA) and neovascular AMD (NV).

Results : For the 9-step scale analyses 6959 eyes (3780 participants) with no late AMD at baseline were analyzed. For late AMD by eye, in a model including this scale and RPD together, the hazard ratio (HR) for RPD was 2.5 (95% confidence limit (CL): 2.1-3.1). In stratified models by the scale the RPD HRs were 5.1 and 1.8 for levels 1-6 and 7-8, respectively. For GA, the RPD HRs were 2.6 (2.2-3.4) (not stratified), 5.9 and 1.9 for levels 1-6 and 7-8, respectively. For NV, the HRs were 1.7 (1.3-2.2) (not stratified), 3.7 and 1.1 for levels 1-6 and 7-8. For the simplified scale analyses 3182 participants with no late AMD at baseline in either eye were analyzed. For late AMD, in a model including this scale and RPD together, the HR for RPD was 2.2 (1.8-2.6). In stratified models by the scale the RPD HRs were 3.2, 3.8, 2.3, and 1.6 for levels 0-1, 2, 3 and 4, respectively. For GA, the RPD HRs were 2.6 (2.1-3.2) (not stratified), 3.5, 4.9, 3.1 and 1.9 for levels 0-1, 2, 3 and 4, respectively. For NV, the HRs were 1.3 (0.9-1.8) (not stratified), 2.9, 3.03, 1.1 and 0.9 for levels 0-1, 2, 3 and 4. The Table includes the 95% CL of the models performed.

Conclusions : RPD represents an important third risk factor for progression to late AMD. This is true for both subtypes of late AMD, particularly for GA. However, the excess risk associated with RPD varies markedly by severity level. It carries highly increased risk at lower/moderate levels and less increased risk at higher levels. RPD status should be included in updated AMD classification systems, risk calculators, and clinical trials.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×